---
title: Antiobesity
author: J. Austin Straley, DO
layout: post
chapter: 9
section: 01
lesson: 13
date: 2023-03-30
---

- Definitions
  - Normal Weight: 18.5-24.9 kg/m^2
  - Overweight: 25-29.9 kg/m^2
    - Measure waist + co-morbidities
    - 25-26.9 + co-morbidities: Lifestyle
    - 27-29.9 + co-morbidities: Lifestyle + Pharmacotherapy
  - Obese: ≥30 kg/m^2
    - Class 1: 30-34.9 kg/m^2
      - Lifestyle + Pharmacotherapy
    - Class 2: 35-39.9 kg/m^2
      - ≥5-10% over 6m goal
      - Healthy: Lifestyle + Pharmacotherapy
      - With co-morbidities: Bariatric Surgery
    - Class 3: ≥40 kg/m^2
      - Bariatric Surgery
- Bariatric Surgery
  - Resolves T2DM in 73%, HTN 63%, OSA 78%, fertility, decreased 4.5y mortality
  - Roux-en-Y gastric Bypass = best, 1yr: 31.2% reduction of weight, 25.5% at 5y
  - Sleeve: 1yr: 25.2% reduction of weight, 18.8% at 5y
  - Adjustable gastric band: 1yr: 13.7% reduction of weight, 11.7% at 5y
  - Thiamine: 12-50mg daily, B12 500mcg daily or 1000mcg monthly, Folate: 400-800mcg daily, vitamin A:5000-10000 IU daily, Vitamin E: 15mg daily, VitK: 90-120mcg daily, D3: 3000IU daily, Calcium: 500-600mg TID, Iron: 18mg-60mg daily, Zinc: 8-22mg daily, Copper 1-2mg daily (8 to 1mg with zinc to prevent copper deficiency)
    - Labs 3-6m in 1st year, Q6 after
    - CBC, CMP, pre-albumin, b12, thiamine, folate, vitamin A and D, PTH, iron, ferritin
- Lifestyle
  - Reduction in 500-750 kcal/day = 1-2 lbs per week
  - 150 up to 300 minutes per week
- Orlistat (Xenical, Alli)
  - Indicated for use ≥3 months
  - Lipase Inhibitor
    - Lowers BP ~10mmHg, reduces total cholesterol, LDL, triglycerides, risk of progression to diabetes, reduces need for diabetes meds
  - 60mg TID to 120mg TID
  - -2.6kg at 6m, -2.9kg at 12m
  - SE: Liver injury, Diarrhea, flatulence, fecal urgency, dyspepsia
- Phentermine/Topiramate (Qsymia/Qnexa)
  - Approved for use ≥3m and \<3m
  - Appetite suppressant
    - Positive effect on CV outcomes, Lowers BP and decreases need for BP meds, increases HR slightly at max dose, reduces need for diabetes meds
  - 8mg TID to 37.5mg daily
  - 5/46mg daily recommended, 15/92mg daily max
    - 1kg at 12m at recommended, -10.2 kg at 12m at max
  - SE: constipation, xerostomia, dizziness, seizure, insomnia, depression, hypohidrosis, angle closure glaucoma, birth defects
- Naltrexone/Bupropion (Contrave)
  - Approved for use ≥3m
  - Appetite suppressant, opioid antagonist/aminoketone antidepressant
    - No CV benefits, reduces waist circumference, triglycerides, and HDL, reduces need for diabetes meds
  - 16/180mg BID
  - -4.1kg at 12m
  - SE: Nausea, constipation, headache, vomiting, seizures, hepatotoxicity, increased BP and HR
- Liraglutide (Saxenda)
  - Appetite suppressant; GLP-1 receptor agonist
    - reduces waist circumference, Lowers BP, reduces LDL and triglycerides, risk of progression to diabetes
  - Approved for use ≥3m
  - 3mg subq daily
  - -4.5kg at 12 months
  - SE: Nausea, hypoglycemia, diarrhea, constipation, headache, pancreatitis, GB disease, thyroid carcinoma, Thyroid tumors
- Semaglutide (Wegovy)
  - Appetite suppressant; GLP-1 receptor agonist
  - Approved for use ≥3m
  - 4mg subq weekly
  - -15.3kg at 14 months
  - SE: Nausea, hypoglycemia, diarrhea, constipation, headache, pancreatitis, GB disease, thyroid carcinoma, Thyroid tumors
- Diethylpropion
  - FDA approved for \<3m
  - 25mg TID
  - SR: 75mg daily
- Phendimetrazine
  - FDA approved for \<3m
  - 5-70mg BID to TID
  - SR: 105mg daily
- Benzphetamine
  - FDA approved for \<3m
  - 20-50mg daily to TID
- Cetilistat
- Lorcaserin (Belviq)
- Metformin
- Exenatide